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Skin-derived Antileukoproteinase (SKALP) and Epidermal Fatty 
Acid-binding Protein (E-FABP) : Two Novel Marl<ers of the 
Psoriatic Phenotype that Respond Differentially to Topical Steroid 
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Dt'/'llf/lllt'll/1' u/ Dtmtuwlogr, 1L iut'l!l'.!tll' Hu.IJIIIa/ Niimegen, T!te .Vedtt•r/wul~ 1111tl '()flil'l:rs/ly Ho>pttal Gt'nna. Swtl:!'l'lrmd. 
Reccotl~ WP ha'e described two nmcl markers for disturbed 
epidermal differentiation. which are ~trongly upregulated in 
P"oriatic epidermis: skin·derhed antileukoproteinase (SKALP) 
and epidermal farty acid-binding prutein ( E-FABP). Ko data 
arc a\ailable on the kinetics of SKALP and E-FABP expression 
;, ,.;,,o and the relatjon with epidermal growth and dHferentjation. 
We used treatment of lesiooal psoriatic skin with topical steroid 
a); " model to correlate the exprtlssion pattern of S KALP and 
E~F'AOP with known cell biological c\'cnts during regression of 
tlw psoriutk lesion. Expression of tbese markers was studied 
u~ing immunohistochemistr~· and Northern blot analysis. After 
-' 1\l't!ks or treltUDeot a substantial Clinical improvement ''as 
induced by the topkal steroid. 1~herea!> no significant impro,·e-
ment had occurred a1 the placeb()- treated ides. The e.x11ressioo 
of KALP following treannent \'lith steroid 11a nearly undetect-
able both at the protein and mRNA fcyel. .\litotic acti-vity, as 
meas-ured h) Ki-67 staining, and cytokcralin 16 expression were 
d<mnregui:Jtcd to normaJ levels in the steroid-treated epidermis. 
ln contrast. although there was 11 marked decrease of E-FABP 
mRNA. the staining pattern for E-FABP at the protein level 
wus oot utrccted. After 4 weeks of treahnent with steroid the 
complete suprubasal compartment remained positive. e,·en after 
considerable dinicaJ impr01ernen1 or the lesion. We conclude 
that K \ LP and cytokeralin J6 a re markers that are downreguJ-
:ued c1en before complete macroscopic clearance of the lesion. 
The kinetics of E-FABP e.xpr~ion is distinct from the other 
molecules and lags behind the clinical signs of psoriasis. Key 
l l'lll'tif: proteinase inhibitor: immunfllli.l'toclu!misrry; psoriasis; 
t'l.ll'tinJSIC'I'Oid. 
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Jn Lbe psonatic lesion epidermal hyperproliferation. infiamma· 
lion and a distmbed differentiation are well-known histological 
fe.1tures, These aberrations can be visualised by immunohisto-
chemicnl ~tainipg of different marker molecules. Some of these 
molecul~. sucl1 as cytokeratin J 6 (CK 16 ). are absent in 
normal epidermis but are c<\presscd in lcsional psoriatic skin. 
rn p~nriatic skm CK 16 is pre~nt in thl.' upper layers of the 
supmbasal comparunent (I. 2) Other dilferentialion-relate.d 
protetns '"luch are restricted to the granular layer u1 nOFITlal 
skm arc strongly expressed in the t.tratum spinosum of lhe 
p~onauc epidermis. Well-known repre!.l!ntallves of this cJass 
of dsUt:rentiation IIUirkers are mvolucrin ( 3, 4) and uansgluta· 
mtnnse ( 5). 
Recently ""o new ep1dennal proteins were described; sian-
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derived antileukoproteinase !SKALP) and epidermal fatty 
ac1d-binding protein ( E-FABP). SKALP. 1dentical to dafin 
( 6 ). i) a potent inhibitor of hum au leukocyte elastase and 
protctnase 3, enzymes which are n:lea:.ed by activated PMN 
I 7) 11 is speculated that SKALP prov1des protection aga.mst 
.::lastase-mediated damage and inhibns PMN migration. 
lmmunoblstochemical staining located the expression of 
SKALP in the upper layers of tht: suprabasal compartment in 
psoriatic skin, whereas uninvolved psoriatic skin and uorma1 
sk.an showed no expression ( 8 ). The expression of mRNA for 
SKA LP. examined by in sill/ hybndirttuon. revealed an mtense 
Sllltning of the supra basal compartment m psoriatic skin C9 ). 
The :.econd novel epidermal protem ll> E-FABP. described 
by o ther:; as psoriasis-associated fatty acid-binding protem 
( PA-FABPl ( 10). which binds fatly acids with high specificity 
(II J ln pre~ious investigation~ the presence of an epidermal 
FABP disttnct from other Li~ue-1-ABP was establjsbed ( 12). 
Exprcss ton levels of E-FABP were upregulated in psori<ttic 
~kin <tnd culwred keratinocytes compared to normal skin, 
l>Uggesting that the stage of keratinocytc diiferentiation is 
related to the expression of E-FABP (II. 10). Immuno-
hbtochemical staining of E-FABP showed t!xpression in the 
stratum granuJosurn and in the ltpper third of tl1e stratum 
splllosum in nomrnl skin an<.l ll(ln-lestonal psoriatic ~kin. ln 
~oriatic ep1dermis E-FABP t'l expressed in all supraba.sal 
layer~ ( I IJ. 
Topical application of corllco~teroids represents an eftective 
trc<tlrncnt of chronic plaque p~oriasi5 ( 13 ). The effect of 
corticosteroids on histological parameters in dermis and epi· 
dennis has been investigated previou~ly ( 14, 15 ). Both the 
number of cycling cells, as marked by positive nuclei in n 
Ki-67 staining. and the CK I n·expressing cells showed u 
marked decrease after only I week of treatment ( 16). Dermal 
polymorphonuclear leukocyte infLltrauon also diminished 
early, ttl contrast w the mononuclcJr cells. which remained 
unchanged after treatmenL 
The a 1m of this study wa:. to mvcsttgate the eilect of LopiC<.tl 
corm·osteroid on the expre~sion levels of two novel marker:. 
or Lb~ psonatic differentiation pmgrnm. We were particularly 
interested in studying whether ~teroids would ttiTect tbe pre-
sumed anti-inflammatory part or the program 1 SKALP expres-
sion) or the regenerative part of the program (E-FABP 
ex pres$ ion). Tbe changes or tlwse markers were related to the 
expressiou of Lwo established markers J'or epidermal prolifera-
tion: the Ki-67 nuclear antigen <lnd CK 16 
MATERIAL AND METHODS 
f'flli~lll\ 
Twelve p~1lienls (7 males and 5 t'cmnks. mean ag<' 52. range 30-671 
with chmntc plaque psoria:;is parttcipHtcd 111 a random.ised, double· 
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blind left-right study. Permission of the medical ethical committee and 
"riuen info-med consent from all pauent> were obtained. The patients 
had not used topical corticosteroids for at least 2 ..-.;eeks. ln this left-
nght study hydrocortisone 17-butyrate 0.1% ( Locoid® CreJo®. 
Yamanouchi. Leiderdorp. the ctherlands) was compared with 
vehicle. Patients applied the creams thinly on the psoriatic lesions 
twice daily during 4 weeks. In one lesion on the left side and one on 
the right side of the body chmcal scores ''ere recorded before treatment 
and after 4 weeks of treatment. Erythema, induration and scaling of 
the lesions were assessed using a five-point scale: O=no cutaneous 
mvolvemenl, I =slight, 2=moderate, 3=severe, 4=severest possible. 
Skin biopsies 
Ln 6 patients punch biopsies ( 4 mm) were taken for histological 
examination. Biopsies were taken from one lesion before treatment 
and from both sides after 4 weeks of treatment. Biopsies were fixed 
m buffered 4% formalin for at least 24 h and processed for routine 
histology. Tissue was embedded in para !lin and 5-lffil sections were cut. 
In the other 6 patients two shave biopsies for RNA measurement 
were taken before therapy. one from uninvolved skin and one from 
Iesional skin. SubsequeOlly, biopsies were t."lken from both sides after 
2 days and 4 weeks of treatment. Biopsies were snap-frozen in Liquid 
nitrogen and stored at - 80 C unul use. 
All biopsy places were marked on a transparent sheet before 
treatment was started. 
lmnnmohistuchemical .\Ienning 
Staining to assess epadermal proliferation and keratinization was 
.:arried out using the following antibodtes: MIB (lmmunotech S.A .. 
\farseille, France), which bmds to the nuclear antigen K.i-67 present 
m cycling cells (17). and Ks8.12 (Sigma. St. Louis. MO. USA). which 
detects CK 16. CK 16 is expressed by hyperproliferative keratinocytes 
· I). Anti-E-FABP serum and ant1-SKALP serum were prepared as 
pre,·iously described ( 8. II ). 
Paraffin sections were dcparaffinised and rehydrated and immuno-
>taining wa; performed. An indirect peroxidase technique was used 
for staining with anti-CK 16 antibodies and the antisera against 
E-FABP at:d SKALP. t:irst, the sections were pre-incubated with 
normal swine serum ( E-FABP, SKALP) or normal rabbit serum 
tCK 16). For staining with the ant i-CK 16 antibodies. slides were 
mcubatcd with the antibody in a d ilution of 1 :25 for 30 min. For 
SKALP and E-FADP stain ing, sections were incubated wi th anti-
SKALP serum at a diJution of 1 :500 and anti-E-FABP serum at a 
dilution of I: 100 for 60 min. After incubation with peroxidase-
conjugated rabbit-anti-mouse lg (CK 16 staining) or peroxidase-
conjugated swine-anti-rabbit lg (SKALP and E-FABP staining). the 
sections were developed with amino-ethylcarbazol as the chromo-
genic substrate. 
For staining of the Ki-67 antigen sections were pre-incubated with 
normal hor;e serum Sub~equently. slide~ were incubated with anti-
K.i-67 antibodies in a dilution of I : 50 for 60 min. After incubation 
with biotinylated borse-anu-mouse lgG (dilution I : 200) for 30 min. 
complexes v.ere formed between baotin and avtdin using the Vectastain 
Elite ABC peroxidase kit, according to the manufacturer's instructions 
Vector Latoratories. Burlingame. USA). The secttons \\'ere de, eloped 
with metal-enhanced diaminobenzidin as the chromogenic substrate. 
His/Oiogicalexaminatiun 
Semiquantitative assessment of the histology was earned out by an 
observer who was unaware of whether sections were derived from 
steroid- or placebo-treated sites. Epidermal proliferation was measured 
by counting the number of K.i-67-positive nuclei per mm length of the 
section. The CK 16, SKALP and E-FABP staining in the epidermis 
was assessed using a five-point scale: O= no staining, l =sporadic 
staining, 2 = wealc staining, 3 =moderate staining. 4 =pronounced 
staining. 
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RNA isolation and Nortlll!m blot analysis 
Total RNA was extracted from shave biopsie~. using RNAzol B. as 
suggested by the supplier (Cinna Biotex Laboratory. Inc .. Houston. 
TX, USA). For Northern blot analysis. 10 ~g of total RNA was 
electrophoresed on a 1"'• agarose gel containing l8°n formaldehyde 
following standard procedures ( 18) and blotted onto a nylon mem-
brane (Boehringer. Mannheim. Gennanyl by capillary transfer. After 
transTer. RNA was fixed to the membrane by ultra,iolet irradiation 
(312 nm, 0.2 J1cm2 ). Hybridis:uion was performed as described previ-
ously using a 0.42 ~bp Pwllf EcoRl fragment of the SKALP eDNA 
clone pGESKA as a probe ( 18). Subsequently. after stripping of the 
membranes with 0.1% SDS 15 mM NaCl 1.5 mM NaCitrate in RNAse-
free water, hybridisation was perfom1ed as described previously using 
the PA-FABP eDNA clone 1592 as probe, which was a kind gift of 
Dr. P. Madsen, Institute of Medical Biochemistry and Danish Centre 
for Human Genome Research. Aarhus University. Denmark 110). 
Control hybridisations for equal loading were performed using a 
human 28 S ribosomal RNA probe. All probes were labelled 1vitb J!p 
by random priming following standard procedures. Autoradiography 
was performed on X-Omat S film (Kodak, France) at - 80 C with 
an intensifying screen. 
Statistical analysi.\ 




The clinical response to treatment with steroid and placebo is 
summarised in Fig. I. Comparing the efficacy of treatment ( = 
scores before treatment - scores after treatment) with steroid 
and efficacy of treatment with placebo, a significant difference 
in favour of the steroid in erythema score and desquamation 
score could be established. No significalll difference in indura-




hydrocortisone 17-butyrate placebo 
Fig. I . The clinical score~ as rated for erythema (black bam. indura-
tion (white hars) and desquamation (hatchl!d hars) before and after 
treatment with hydrocortisone 17-butyratc and placebo, expressed as 
mean values ± SEM. Comparing the efficacy of treaonent (=scores 
before treatment - scores after treatment) with steroid and \\itb pla-
cebo, a significant difference in favour of the steroid in erythema score 
(p<0.03, Wilcoxon ranking test) a nd desquamation score (p<0.05, 
Wilcoxon ranking test) was l'ound. 
"cia f)erm Venereol (SIOckh ) 77 
16 t l. L. A. Kuijpe!r.l C!l a/. 
Table I. Mmn wt!uc.v 11/' 1he 111/trkers .for pm/ij(•ration a111/ 
dij)erc/1/illlillll ± s n 
The CK 16. SKALP and 1"-FA BP :.tain111g in the epidermis \vtt~ 
<t~~e:.~ed u-.mg a fin:-po1111 -,c;tlc: 0 =no >taining. I =sporadic stain mg. 
~=\\cal. stainmg. ' moderate \Wtning. 4 =pronounced staining. 
Ki-67 Manung "'" mca-,urcd by counllllg the number of positive 
nuclei per mm length or th.: "-'t:tion. Comparison wa~ made betwc:.:n 
\.tllll~'> t>t:ft•rc: treatment and after trcatmclll \Vilh hydrocortisone 
1"'-bul}rat.: 11.1". and pl.teebo. rc:.pecllvel} (*t•<O.OI. Wilcoxon 
ranking lt:"l I 
An ligen Week 0 Week 4 Wed 4 
Steroid Placeho 
SKALP 3.2±0.-1 0.3±0.5* 3.3 j:0.5 
E-FA BP 3.4 ± 0.5 2.8±0.7 3.5±0.5 
Cyto f..~ra tin 16 \;!±0.5 0.2 ± 0.-1* J.l ±0.9 
Ki-67 \llUH 31.5 12.5±5.0* 72.5 ..t33 8 
!ttllllllllt l!t is I od1et11 i('ll I tlh.V<'I'I'UI ions 
St:miquantitative data on the staining patterns of the ditferent 
antibodies arc prcs~.:ntcd in Table I. In the untreated psoriatic 
lesion SKA LP cxprcs:-.ion i~ seen in tht: suprt~basa l compart-
ment (Fig. 2a). After 4 weeks or trt:atmt:nt wi th steroid. a 
;,ignificant decrea~e in SKA LP expression could be seen 
(Fig. 2b). In 2 patienh u 'hght staining was still present afte r 
treatment \\ith :-.teroid. S KALP expression was completel> 
ab~ent in the other patients. The placebo-treated lesions 
shO\\ed no signtficant decrease of SKALP-positive eelb 
( Fig. 2c). 
Before treatment. the E-FA BP staining was prominent in 
all the supraba!>allayers of the epidermis ( F ig. 3a). In contrast 
to all other markers ~tained. E-FA BP expression in the steroid-
t reated lesions did not return to the normal pattern (i.e. 
expression limited to the ~tratum granulosum as described 
before). The E-1-A BP staini ng in the steroid-treated lesions 
(Fig. 3b) is similar to that in the placebo-treated lesions 
( Fig. 3c). showing po:,itive staining in the entire st ratum 
spinosum . 
In this study we found a st rong eiTect or topical steroid on 
CK 16 (nearly undetcct<tblc in most biopsies) and Ki-67 
expression. which was downmodul<tted to the level found in 
normal skin ( 12.8 ± 1.5 cells per mm) ( 19 ). 
Nortltem blot ana~1'.1i.1 
Before treatment. sha\'e biopsies were taken from 6 patients 
from lesional and non-lesional skin. Biopsies were repeated 
after 2 days and 4 \\eek:. from a steroid- and a placebo-treated 
lesion. Fig. 4 !>how!> the presence of SKA LP mRNA (Fig 4a) 
and E-FABP rnR A (Fig. 4b) in the biopsies taken from 2 
representative patienb. In untrea ted psoriatic skin a strong 
expression of SKALP rnR A could be denronstrated. whereas 
the unin\'olvcd skin :.howed no cxpre~si'on . After 2 days 
SKALP mRNA in the steroid-treated lesions showed no 
decrease. remaining equal to the placebo-treated lesions,..After 
4 weeh of treatment wi th placebo SKALP mRNA expression 
was still high, wherca:. a weak signal was found in the stero id-
treated le:.ions. However, in none of the patients did steroid 





Fig.:!. (u) The SKALP C.\pr~>s i on bcfor.: treatment. ~KALP is seen 
in the supraha:,;d l;tycr~ vf the cptdcnni~. (h) Tho: SKALP expression 
after 4 week:. of trc<llll1Cill with hydrocorli>OtH.' 17-hutyrate. SKALP 
wa~ only ~l i ghtly cxpto:"cd. (I') The SKALP expression after 4 wceb 
of treatment wrth r laccbo is comparahle with th~: <.:xprcssion we 
obsened before the trcauncnt period. Bar. 100 ).tm. 
The cxprc~:.ion of E-rA BP mR A in untreated psonauc 
:.kin i~ strong: uninvolved skin ~hO\\!> no detectable expression 
(Pig 4b ). Remarkabl). after 2 da}s· treatment \\ ith ~teroid. 
E-FA BP mR A C\prcssion was s ubstantially decreal>ed. After 
4 week.s both placebo- •md steroid-treated psoriatic skin 
showed a marked decrease or E-FA BP rnR A expression, 
with a morc pronounced decrease in the steroid-trea ted lesions. 
DISCUSSION 
Since the aetiology of psoriasis is unknown and the patho-
genesis is only partially understood. we st ill do not know th~: 
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Fig. 3. ( a) E-FABP staining before treatment. E-FABP is expressed in all supra basal layers of the epidermis, the basal layer being completel:, 
negative. (b) The E-FABP expression after 4 weeks of steroid treatment. There was a slight reduction in expression of E-FABP, but it d id not 
return to normal. tc) The E-FABP expression after 4 weeks of treatment with placebo is comparable with the expression we observed before the 
ueatment period. Bar, 100 1-UJl. 
rational base of most aotipsoriat ic therapies used. Studying 
the sequence of events at the cell biological level in the 
regression phase of a lesion during treatment could provide 
us with clues to the mode of action of a specific treatment and 
.:ontribute to our understanding of the pathogenesis. 
We have investigated the response of several markers of the 
psoriatic phenotype to treatment with 10pical steroid. In a 
previous study ( 16) we have shown that keratin 16 staining 
and Ki-67 expression in psoriatic epidermis were markedly 
downregulated under s teroid treatment. Despite the use of a 
a less potent class li stewid in present study for 4 weeks, a 
'1gnificant improvement of the lesions was seen compared to 
placebo. Remarkably, cellular proliferation, CK 16 expression 
and SKALP expression were found to be completely nor-
malised in most patients, despite the fact that clinical scores 
were not completely normalised (compare Table I and Fig. I). 
E-FABP. l10wever. continued to be expressed throughout the 
!ntire suprabasal compartment after 4 weeks of treatment, in 
:ill patients. These fiJlClings show that cell biological alterations 
-ound in psoriatic epidermis do not necessarily display sim-
ilar kinetics. 
Previous studies from our group have shown that SKALP 
is absent in normal skin and that it is induced in psonat1c 
skin and during injury (8, 20). We have described the distribu-
tion in the margin zone or psoriatic plaques (21) and the 
induction and regression in annular pustular psoriasis (22). 
Based on the finding that SKALP is a potent and specific 
inhibitor of PMN-derived proteinases (7) we assume that it 
controls PMN-dependent proteolysis in cutaneous inflamma-
tion. In vivo SKALP expression is putatively linked to the 
presence of elastase-containing cells (PMN and monocytes) in 
the inflamed skin. In this study we have shown that SKALP 
is downmodulated after 4 weeks of topical steroid. The finding 
that after 2 days of therapy the levels of SKALP mRNA are 
simiJar in steroid- and placebo-treated skin indicates that it is 
w1likely that SKALP is affected at the transcriptional level by 
steroid. SK.ALP downregulation is probably not a di rect effect 
of the steroid at the transcriptional level but is rather a 
consequence of normalisation (healing) of the tissue. We 
therefore assume that steroid-treatment decreases the cellula r 
infi ltrate and that consequently SKALP expression in the 
epidermis is downmodulated. 
E-FABP, also known as psoriasis-associated fatty-acid-
binding protein ( 10), is a recently described member of the 
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Fig. 4. Northern blot of SKA LP and E-FA BP mRNA in skin biopsies 
of 2 representative psoriatic pmicnts treated in a left-right study with 
hydrocortisone 17-butyrate and placebo. Lane I = uninvolved skin, 
lane :.'=psoriatic skin before treatment; lane., 3-6 represent biopsies 
taken in 2 represent•ltive patients after 2 days of treatment (lanes 
3 +4 and lanes 5 + 6. respectively); lanes 3 + 5 =after 2 days' treatment 
with steroid, la11e~ 4 +6 =after 2 days' treatment with placebo.: 
Lanes 7- 10 n:present biopsies taken in 2 representative patients after 
~ \\eek!. of treatment (lanes 7 +8 and lanes 9 + 10, respectively): 
lane., 7 + 9=after 4 weeks' treatment with steroid. lanes 8 + IO=after 
4 weeks' treatment'' ith placebo. In the upper panels a probe for 28S 
nbosomal Rl'<A was used for control hybridizations to check for 
equal RNA loading. 
a. Lower panel. Before treatment no expres~ion of SKALP could be 
demonstrated rn umnvolvcd sktn (/a11e 1). "'hereas psoriatic skin 
shO\\ed a \trong expre~sion Otm( ..? 1. After 2 days of treatment the 
expression in the ;,tcrOid-treated lc\lon-, (lane.\ 3 + 5) and the placebo-
ueated lestons (lane~ 4 +61 was equal. After 4 \\ecks of treatment no 
stgnificant decrease tn SKALP mRNA was found in the placebo-
treated les10ns (/am's 8+10). Compared with placebo. the mRNA 
expre:.sion m the sterold-treated lesions (lanes 7 + 9) is suongly 
decreased. \~hich is in agreement with the data on the protein level. 
b. Lower panel. Before treatment no expression of E-FABP could be 
demonstrated in unillVolved skin (lane I), whereas psoriastic skin 
showed a strong expression (lane ..? ). After 2 days of treatment the 
expression in the steroid-treated lesions (lanes 3 + 5) was decreased, 
whereas pl~tcebo-tn:;sted lesions (lanes 4 +6 ) showed no decrease. After 
4 weeks of treatment the mRN/\ expression in both the >tcroid-treated 
lesions (lanes 7 + 9) and the place bo-t rea ted lesions is decreased. with 
a more pronounced decrease in the placebo-treated lesions 
(lanes 8 + 10). 
C)1oplasmic fatty acid binding proteins ( 12. 23 ). It is expressed 
at relatively low levels in nom1al epidermis (restricted to the 
granular layer) but is strongly upregulated in psoriatic epi-
dermis (I L 10). The mechanism of its induction and its precise 
fw1ction are not understood at the moment. E-FABP bas a 
high affitin) for C-18 fatty acids but is not involved in 
arachidonic acid binding. A function ofE-FABP as a scavenger 
of arachidonic acid to control inflammation is therefore 
unlikely. This agrees with the finding thar· E-FABP is still 
increased after 4 weeks of steroid therapy. tn contrast to the 
persisting expression of E-FABP in the suprabasal layers even 
after 4 weeks' treatment, Northem blot analysis revealed a 
decrease in mRNA expression after 2 days of treatment with 
steroid. Whether this finding implicates that steroids have a 
direct influence at the transcriptional level requires further 
study. 
Spcculative1y, increased E-FABP expression in psoriasis 
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could be involved in barrier function (enhanced transport of 
lipids). Studies on restoration of barrier function in healing 
psoriatic leasion~ have shown that barrier function is still 
impaired even after complete clearing of the lesions after 
dithranol treatment (24 ). We therefore speculate that the 
persistent E-FABP expression is associated with a continuolb 
high fauy acid transport. which is needed for restoration of 
barrier function. We have recently completed a study on the 
cell biological alterations during irritant contact dermatitis. 
which strongly suggests that E-FABP expression is increased 
following barrier disruption. 
In conclusion. E-FA BP expression in psoriatic skin is a cell 
biological marker that is distinct from other markers such as 
CK 16, SKALP and cellular proliferation, which are downreg· 
ulated even before complete clinical normalisation. Our stud) 
indicates that E-FABP expression lags behind the clinical signs 
of psoriasis. 
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